SITC covers immunotherapy specifically, not oncology broadly, which makes it one of the sharpest filters on the entire life science conference calendar. A company exhibiting or presenting here is telling you, directly and publicly, that it has an active immuno-oncology program, months before that shows up anywhere else.
What SITC is
The Society for Immunotherapy of Cancer Annual Meeting focuses on cancer immunotherapy: checkpoint inhibitors, cell therapies, bispecifics, and other immune-based approaches to treating cancer. It draws a narrower and more specialized audience than a general oncology meeting like ASCO, biotech and pharma companies with immunotherapy pipelines, along with the CROs, CDMOs, and specialty labs that support cell therapy and immune-based drug development.
The GTM signal at SITC
Exhibiting at SITC is a stronger, more specific signal than exhibiting at a broad oncology show, because the audience filter is already done for you: it means real budget committed to visibility in front of an immunotherapy-specific crowd. A named presenter is an equally sharp contact-level hook, a specific person tied to a specific immunotherapy dataset. Even attendance alone, the weakest of the three signals, is a meaningfully tighter filter here than at a broad show, since the audience itself is already immuno-oncology-specific. See selling around life science conferences for how to weigh the three signals.
The outreach window
As with the other flagship oncology shows, exhibitor lists and accepted abstracts become public in the weeks before the meeting, giving a lead-time window to cross-reference against your immuno-oncology account list and plan specific, timely outreach before the show opens. On-site outreach during the show still works as a fallback for accounts identified late. The useful follow-up window after SITC closes runs a few weeks before a reference to the meeting stops reading as current.
Who this matters most for
A CRO running or pursuing immuno-oncology or cell therapy trials should treat SITC as one of the highest- signal shows available, sharper than ASCO for that specific pipeline. A CDMO with cell therapy manufacturing capability should watch SITC exhibitor activity closely, since it is a near-direct match for that buyer. A tools or reagents vendor serving immunology or cell-therapy workflows will find SITC a tighter fit than a general oncology or immunology show.